Inflammatory Bowel Disease and Risk of Cholangiocarcinoma: Evidence from a Meta-analysis of Population-based Studies

  • Huai, Jia-Ping (Department of Critical Care Medicine, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University) ;
  • Ding, Jin (Department of Gastroenterology and Hepatology, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University) ;
  • Ye, Xiao-Hua (Department of Gastroenterology and Hepatology, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University) ;
  • Chen, Yan-Ping (Department of Gastroenterology and Hepatology, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University)
  • Published : 2014.04.30


Objective: Patients with inflammatory bowel disease (IBD) have an increased risk of extra-intestinal cancer, whereas its impact on cholangiocarcinoma (CC) remains unknown. The aim of this study was to obtain a reliable estimate of the risk of CC in IBD patients through a meta-analysis of clinical observational studies. Methods: Relevant studies were retrieved by searching PUBMED, EMBASE and Web of Science Databases up to Dec 2013. Four population-based case-control and two cohort studies with IBD were identified. Summary relative risk (RR) and its corresponding 95% confidence interval (CI) were calculated using a random-effects model. Potential sources of heterogeneity were detected using subgroup analyses. Results: The pooled risk estimate indicated IBD patients were at increased risk of CC (RR = 2.63, 95%CI = 1.47-4.72). Moreover, the increased risk of CC was also associated with Crohn's disease (RR = 2.69, 95%CI = 1.59-4.55) and ulcerative colitis (RR = 3.40, 95%CI = 2.50-4.62). In addition, site-specific analyses revealed that IBD patients had an increased risk of intrahepatic CC (ICC) (RR = 2.61, 95%CI = 1.72-3.95) and extrahepatic CC (ECC) (RR = 1.47, 95%CI = 1.10-1.97). Conclusions: This study suggests the risk of CC is significantly increased among IBD patients, especially in ICC cases. Further studies are warranted to enable definite conclusions to be drawn.


  1. Barusrux S, Nanok C, Puthisawas W, et al (2012). Viral hepatitis B, C infection and genotype distribution among cholangiocarcinoma patients in northeast Thailand. Asian Pac J Cancer Prev, 13, 83-7.
  2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  3. Blechacz BR, Gores GJ (2008). Cholangiocarcinoma. Clin Liver Dis, 12, 131-50, ix.
  4. Chang JS, Tsai CR, Chen LT (2013). Medical risk factors associated with cholangiocarcinoma in taiwan: a populationbased case-control study. PLoS One, 8, e69981.
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  7. El-Serag HB, Engels EA, Landgren O, et al (2009). Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology, 49, 116-23.
  8. Erichsen R, Jepsen P, Vilstrup H, et al (2009). Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol, 24, 513-20.
  9. Gatto M, Bragazzi MC, Semeraro R, et al (2010). Cholangiocarcinoma: update and future perspectives. Dig Liver Dis, 42, 253-60.
  10. Hamling J, Lee P, Weitkunat R, Ambuhl M (2008). Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med, 27, 954-70.
  11. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  12. Hussain SM, Al-Jashamy KA (2013). Determination of chemical composition of gallbladder stones and their association with induction of cholangiocarcinoma. Asian Pac J Cancer Prev, 14, 6257-60.
  13. Jacobsen BA, Fallingborg J, Rasmussen HH, et al (2006). Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol, 18, 601-6.
  14. Jess T, Gamborg M, Matzen P, et al (2005). Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol, 100, 2724-9.
  15. Jess T, Rungoe C, Peyrin-Biroulet L (2012). Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol, 10, 639-45.
  16. Lazaridis KN, Gores GJ (2005). Cholangiocarcinoma. Gastroenterology, 128, 1655-67.
  17. Loftus EV, Jr., Harewood GC, Loftus CG, et al (2005). PSC-IBD:a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut, 54, 91-6.
  18. Luciani MG, Campregher C, Fortune JM, et al (2007). 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology, 132, 221-35.
  19. Manwong M, Songserm N, Promthet S, et al (2013). Risk factors for cholangiocarcinoma in the lower part of northeast Thailand: a hospital-based case-control study. Asian Pac J Cancer Prev, 14, 5953-6.
  20. O’Toole A, Alakkari A, Keegan D, et al (2012). Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol, 10, 439-41.
  21. Palmer WC, Patel T (2012). Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol, 57, 69-76.
  22. Patel T (2006). Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3, 33-42.
  23. Patel T (2011). Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol, 8, 189-200.
  24. Pedersen N, Duricova D, Elkjaer M, et al (2010). Risk of extra-intestinal cancer in inflammatory bowel disease:meta-analysis of population-based cohort studies. Am J Gastroenterol, 105, 1480-7.
  25. Saich R, Chapman R (2008). Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol, 14, 331-7.
  26. Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25.
  27. Shaib YH, El-Serag HB, Davila JA, et al (2005). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology, 128, 620-6.
  28. Shivananda S, Lennard-Jones J, Logan R, et al (1996). Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (ECIBD). Gut, 39, 690-7.
  29. Songserm N, Promthet S, Wiangnon S, et al (2012). Prevalence and co-infection of intestinal parasites among Thai rural residents at high-risk of developing cholangiocarcinoma:a cross-sectional study in a prospective cohort study. Asian Pac J Cancer Prev, 13, 6175-9.
  30. Sripa B, Pairojkul C (2008). Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol, 24, 349-56.
  31. Srivatanakul P, Honjo S, Kittiwatanachot P, et al (2010). Hepatitis viruses and risk of cholangiocarcinoma in northeast Thailand. Asian Pac J Cancer Prev, 11, 985-8.
  32. Tyson GL, El-Serag HB (2011). Risk factors for cholangiocarcinoma. Hepatology, 54, 173-84.
  33. Vind I, Riis L, Jess T, et al (2006). Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a populationbased study from the Danish Crohn colitis database. Am J Gastroenterol, 101, 1274-82.
  34. Wells G, Shea B, O'connell D, et al (2000). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
  35. Welzel TM, Graubard BI, El-Serag HB, et al (2006). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol, 5, 1221-8.
  36. Welzel TM, Mellemkjaer L, Gloria G, et al (2007). Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer, 120, 638-41.

Cited by

  1. An Interleukin-6 Receptor Polymorphism is Associated with Opisthorchiasis-Linked Cholangiocarcinoma Risk in Thailand vol.15, pp.13, 2014,
  2. Histopathological Profile of Benign Colorectal Diseases in Al-Madinah Region of Saudi Arabia vol.15, pp.18, 2014,
  3. Novel Mutations in Cholangiocarcinoma with Low Frequencies Revealed by Whole Mitochondrial Genome Sequencing vol.16, pp.5, 2015,
  4. The Carcinogenic Liver Fluke Opisthorchis viverrini is a Reservoir for Species of Helicobacter vol.16, pp.5, 2015,
  5. Expression of Lamininγ2 in Extrahepatic Cholangiocarcinoma Tissues and its Influence on Tumor Invasion and Metastasis vol.16, pp.5, 2015,
  6. Piperine Suppresses the Expression of CXCL8 in Lipopolysaccharide-Activated SW480 and HT-29 Cells via Downregulating the Mitogen-Activated Protein Kinase Pathways vol.38, pp.3, 2015,
  7. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease vol.15, pp.3, 2017,
  8. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults pp.00207136, 2018,
  9. Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis vol.16, pp.1, 2018,